A new Xarelto lawsuit has been filed in West Virginia by a woman whose episode of gastrointestinal bleeding was allegedly caused by the blood thinner.
According to a report in the State Journal, the case was filed on December 23rd in Charleston and alleges the drug manufacturer’s failure to properly warn about its product’s risk for life-altering complications. Xarelto is an oral anticoagulant prescribed to patients with atrial fibrillation, and to prevent strokes and heart attacks in individuals who may be susceptible. Jointly manufactured by Johnson & Johnson’s Janssen unit and Bayer Healthcare, the drug is also approved by the U.S. Food and Drug Administration (FDA) to reduce the risk for pulmonary embolism and deep vein thrombosis.
The complaint, which was filed by the alleged Xarelto internal bleeding victim and her husband, includes possible inaccuracies about the manufacturer’s marketing claims. When Xarelto was approved in 2011, the Institute of Safe Medication Practices states that “FDA (reviewers) also questioned the convenient once-a-day dosing scheme … (saying) blood level studies had shown peaks and troughs that could be eliminated by twice-a-day dosing…,” the Xarelto bleeding lawsuit states.
This is in reference to Janssen & Bayer’s claims that this new-generation blood thinner, which belongs to the same class as Boehringer Ingelheim’s Pradaxa, is more convenient to patients because it doesn’t require regular monitoring of blood levels. Warfarin, in contrast, requires routine medical check-ups and certain dietary restrictions coupled with its use.
The Xarelto plaintiff in this case alleges that Johnson & Johnson and Janssen’s claims about its product’s convenience are inaccurate, and that the companies were negligent in properly testing it for safety. They also fraudulently concealed side effects from the general public, who were unknowingly at an increased risk for life-threatening episodes of internal bleeding.
It is unclear whether this Xarelto lawsuit will join the number of others that were recently transferred to a newly-created multidistrict litigation in the U.S. District Court, Eastern District of Louisiana. Established on December 12th, the federal proceeding includes similar claims from individuals who sustained injuries allegedly due to the blood thinner.
Parties involved in the litigation will convene for its first status conference on January 29, 2015, according to court records.
Call a Xarelto lawyer today for more information about side effects of the medication, and whether you are eligible to file a claim against Janssen and Bayer. Contact us now at .